nucresiran

all catalysts(0)

nothing on the calendar yet

News(2)

• 5 companies advancing ATTR assets in the wake of Wainua’s fail
  The Phase 3 failure of AstraZeneca and Ionis Pharmaceuticals’ antisense therapy in transthyretin amyloid cardiomyopathy last month left the space reeling—and readjusting. BioSpace looks at five con…
  biospace · 9d ago
• Alnylam absorbs $10.8B blowback after cutting full-year guidance for TTR franchise
  Alnylam’s revenue cut “may create a near term credibility overhang and could “raise questions on peak sales potential, even if there’s tailwinds in the competitive landscape,” according to Stifel.
  biospace · 11d ago